ATXA Therapeutics
Eamon Mulvaney has a Ph.D. in Biochemistry and Molecular Biology and has worked as a Senior Scientist at ATXA Therapeutics Limited since January 2016. Prior to this, they held roles as a Research Scientist in drug development and as a Postdoctoral Research Fellow at University College Dublin. Eamon also served as a Management Associate at Bank of Ireland, focusing on Group Credit & Market Risk. Their expertise lies in drug development and research in the field of biochemistry.
ATXA Therapeutics
ATXA is focusing on late-stage preclinical & clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension.